| scholarly article | Q13442814 |
| P50 | author | Arata Tomiyama | Q42322642 |
| P2093 | author name string | Kentaro Mori | |
| Tatsuya Kobayashi | |||
| Koichi Ichimura | |||
| P2860 | cites work | A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55 | Q24294369 |
| ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage | Q24306743 | ||
| Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions | Q24313501 | ||
| A novel GTPase-activating protein for Rho interacts with a PDZ domain of the protein-tyrosine phosphatase PTPL1 | Q24313540 | ||
| Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent | Q24313879 | ||
| Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET | Q24318458 | ||
| Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion | Q24319686 | ||
| Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2 | Q24319816 | ||
| Indomethacin induced glioma apoptosis involving ceramide signals. | Q52730975 | ||
| PRL-3 promotes gastric cancer peritoneal metastasis via the PI3K/AKT signaling pathway in vitro and in vivo. | Q54977995 | ||
| Global assessment of its network dynamics reveals that the kinase Plk1 inhibits the phosphatase PP6 to promote Aurora A activity. | Q54979032 | ||
| Adenovirus-mediated transfer of Fas ligand gene augments radiation-induced apoptosis in U-373MG glioma cells. | Q55278690 | ||
| Inhibition of Fas associated phosphatase 1 (Fap1) facilitates apoptosis of colon cancer stem cells and enhances the effects of oxaliplatin. | Q55285088 | ||
| The repair of gamma-radiation-induced DNA damage is inhibited by microcystin-LR, the PP1 and PP2A phosphatase inhibitor. | Q55470644 | ||
| Targeting PP2A in cancer: Combination therapies | Q58542302 | ||
| Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma | Q58573420 | ||
| Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma | Q58615747 | ||
| Off-target inhibition by active site-targeting SHP2 inhibitors | Q58804985 | ||
| The multiple functions of protein phosphatase 6 | Q59356193 | ||
| Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling | Q59810447 | ||
| PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells | Q60211787 | ||
| Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma | Q61794394 | ||
| Three forms of RPTP-beta are differentially expressed during gliogenesis in the developing rat brain and during glial cell differentiation in culture | Q71302841 | ||
| Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes | Q74415871 | ||
| Protein phosphatase PP4 is overexpressed in human breast and lung tumors | Q83218848 | ||
| Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment? | Q89168087 | ||
| Proteasome mediated degradation of CDC25C and Cyclin B1 in Demethoxycurcumin treated human glioma U87 MG cells to trigger G2/M cell cycle arrest | Q90228915 | ||
| PTEN: Tumor Suppressor and Metabolic Regulator | Q90429880 | ||
| World Health Organization 2016 Classification of Central Nervous System Tumors | Q90719454 | ||
| RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers | Q90929256 | ||
| Signal transduction pathways and resistance to targeted therapies in glioma | Q91236775 | ||
| Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma | Q24324162 | ||
| KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases | Q24336439 | ||
| A human transmembrane protein-tyrosine-phosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases | Q24337062 | ||
| PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum | Q24337674 | ||
| Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway | Q24338396 | ||
| Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen | Q24603984 | ||
| Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis | Q24632905 | ||
| PTPmu suppresses glioma cell migration and dispersal | Q24650475 | ||
| Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration | Q24650562 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance | Q26739246 | ||
| The emerging role of FTY720 (Fingolimod) in cancer treatment | Q26748927 | ||
| Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases | Q27644421 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers | Q28115840 | ||
| A role for receptor tyrosine phosphatase zeta in glioma cell migration | Q28209273 | ||
| Identification of the homophilic binding site of the receptor protein tyrosine phosphatase PTP mu | Q28240930 | ||
| The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation | Q28240978 | ||
| Serine/threonine phosphatases: mechanism through structure | Q28263239 | ||
| Protein tyrosine phosphatases in the human genome | Q28265924 | ||
| Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia | Q28298677 | ||
| The somatic genomic landscape of glioblastoma | Q28300185 | ||
| Assignment of the human protein tyrosine phosphatase, receptor-type, zeta (PTPRZ) gene to chromosome band 7q31.3 | Q28300741 | ||
| The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer | Q36804492 | ||
| Protein phosphatase 5. | Q36906005 | ||
| PTPL1: a large phosphatase with a split personality | Q37081432 | ||
| The tyrosine phosphatase Shp2 (PTPN11) in cancer. | Q37088972 | ||
| Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease | Q37094068 | ||
| PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis | Q37157031 | ||
| Protein phosphatase 2A regulatory subunits and cancer. | Q37202956 | ||
| Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms | Q37261795 | ||
| PRL3-zumab, a first-in-class humanized antibody for cancer therapy. | Q37277211 | ||
| Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial | Q37278379 | ||
| An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors | Q37294205 | ||
| The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. | Q37300370 | ||
| Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. | Q37340004 | ||
| Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia | Q37372285 | ||
| Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma | Q37385138 | ||
| Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. | Q37524180 | ||
| Protein tyrosine phosphatases in glioma biology | Q37638344 | ||
| Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia | Q37707099 | ||
| Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence | Q37744363 | ||
| Atypical protein phosphatases: emerging players in cellular signaling | Q38084832 | ||
| Targeting DUSPs in glioblastomas - wielding a double-edged sword? | Q38155122 | ||
| Translational gap in glioma research. | Q38245089 | ||
| The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation | Q38352009 | ||
| Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma | Q38438854 | ||
| Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion | Q38737137 | ||
| Src Family Kinases Are Regulated in Multiple Myeloma Cells by Phosphatase of Regenerating Liver-3. | Q38742660 | ||
| Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase | Q38763126 | ||
| Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. | Q38778367 | ||
| Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration | Q38786529 | ||
| PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells | Q38817398 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Reengineered tricyclic anti-cancer agents. | Q38835177 | ||
| Plumbagin inhibits growth of gliomas in vivo via suppression of FOXM1 expression | Q38855400 | ||
| Inhibition of SHP-2 promotes radiosensitivity in glioma | Q38871453 | ||
| Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition | Q34649774 | ||
| Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion | Q34731436 | ||
| The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease. | Q35118478 | ||
| Phosphacan, a chondroitin sulfate proteoglycan of brain that interacts with neurons and neural cell-adhesion molecules, is an extracellular variant of a receptor-type protein tyrosine phosphatase | Q35119836 | ||
| Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution | Q35157212 | ||
| Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties | Q35243673 | ||
| Prognostic role of CIP2A expression in serous ovarian cancer | Q35263210 | ||
| High expression of protein phosphatase 4 is associated with the aggressive malignant behavior of colorectal carcinoma | Q35559402 | ||
| Functional dissection of eyes absent reveals new modes of regulation within the retinal determination gene network. | Q35662554 | ||
| Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability | Q35747245 | ||
| Prognostic significance of CDC25B expression in gliomas | Q35770127 | ||
| Belonging to a network--microRNAs, extracellular vesicles, and the glioblastoma microenvironment | Q35788575 | ||
| Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma. | Q35836388 | ||
| Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A | Q35861815 | ||
| Targeting of a distinctive protein-serine phosphatase to the protein kinase-like domain of the atrial natriuretic peptide receptor | Q35894619 | ||
| Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma | Q35917698 | ||
| Functions of Shp2 in cancer | Q36057452 | ||
| Impaired learning with enhanced hippocampal long-term potentiation in PTPdelta-deficient mice | Q36080560 | ||
| DUSPs, to MAP kinases and beyond. | Q36123161 | ||
| Protein phosphatase 4--from obscurity to vital functions | Q36137554 | ||
| Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma | Q36160050 | ||
| PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome | Q36179171 | ||
| Profiling of UV-induced ATM/ATR signaling pathways. | Q36288898 | ||
| The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth | Q36483794 | ||
| Phosphorylation of protein kinase Cdelta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1: role in the apoptotic effect of etoposide | Q36719264 | ||
| Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. | Q36734746 | ||
| Molecular evidence of cryptotanshinone for treatment and prevention of human cancer | Q36763730 | ||
| Serine/Threonine Protein Phosphatase-5 Accelerates Cell Growth and Migration in Human Glioma | Q38896812 | ||
| Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options. | Q38904928 | ||
| Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1. | Q38926667 | ||
| KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway | Q39007424 | ||
| PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas | Q39025707 | ||
| Regulation of protein phosphatase 2A (PP2A) tumor suppressor function by PME-1. | Q39027999 | ||
| Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer | Q39088131 | ||
| Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling | Q39143478 | ||
| NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability. | Q39218657 | ||
| Anisomycin induces glioma cell death via down-regulation of PP2A catalytic subunit in vitro | Q39267173 | ||
| Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas | Q39333118 | ||
| Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion | Q39354733 | ||
| A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells | Q39535302 | ||
| Clonal evolution of glioblastoma under therapy. | Q39704836 | ||
| CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples | Q39729874 | ||
| Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells | Q39745087 | ||
| The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma | Q39764965 | ||
| Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway | Q39802740 | ||
| A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage | Q40012129 | ||
| Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. | Q40127963 | ||
| RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo | Q40241308 | ||
| Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases. | Q40315744 | ||
| GL15 and U251 glioblastoma-derived human cell lines are peculiarly susceptible to induction of mitotic death by very low concentrations of okadaic acid. | Q40334182 | ||
| FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS. | Q40368462 | ||
| Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial | Q40389926 | ||
| PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis | Q40443869 | ||
| Gene amplifications in osteosarcoma-CGH microarray analysis | Q40493028 | ||
| Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas | Q40604566 | ||
| Do phosphatase of regenerating liver-3, matrix metalloproteinases-2, matrix metalloproteinases-9, and epidermal growth factor receptor-1 predict response to therapy and survival in glioblastoma multiforme? | Q40627498 | ||
| Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. | Q40859498 | ||
| Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation | Q41082492 | ||
| Differential activities in adhesion and neurite growth of fibronectin type III repeats in the PTP-delta extracellular domain | Q41283116 | ||
| Deletion of Ptp4a3 reduces clonogenicity and tumor-initiation ability of colitis-associated cancer cells in mice | Q41911593 | ||
| Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. | Q42152408 | ||
| Eya2 overexpression promotes the invasion of human astrocytoma through the regulation of ERK/MMP9 signaling | Q42280231 | ||
| Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. | Q43747154 | ||
| Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling | Q44234668 | ||
| Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer | Q44346549 | ||
| 2016 World Health Organization Classification of Central Nervous System Tumors: An Era of Molecular Biology | Q46228222 | ||
| Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. | Q46410671 | ||
| A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. | Q46423964 | ||
| Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors | Q46641112 | ||
| CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas | Q46761982 | ||
| The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas | Q46894619 | ||
| Identification of Candidate Casein Kinase 2 Substrates in Mitosis by Quantitative Phosphoproteomics. | Q47158890 | ||
| Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance | Q47627160 | ||
| PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas | Q47740646 | ||
| Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. | Q52646137 | ||
| PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways. | Q52647666 | ||
| Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications | Q47894744 | ||
| Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma | Q48315949 | ||
| Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multi-drug Resistance in Human Glioblastoma Cells. | Q48325028 | ||
| The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells | Q48362692 | ||
| Triptolide inhibits proliferation and invasion of malignant glioma cells | Q48529080 | ||
| Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin | Q48536258 | ||
| PRL-3 promotes breast cancer progression by downregulating p14ARF-mediated p53 expression | Q49997208 | ||
| Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. | Q50100856 | ||
| Geranylnaringenin (CG902) inhibits constitutive and inducible STAT3 activation through the activation of SHP-2 tyrosine phosphatase. | Q50245919 | ||
| Protein Phosphatase 2A in the Regulation of Wnt Signaling, Stem Cells, and Cancer. | Q50421347 | ||
| Key insights into the protein tyrosine phosphatase PTPN11/SHP2 associated with noonan syndrome and cancer. | Q51096263 | ||
| PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. | Q51798437 | ||
| Coordinating proliferation and tissue specification to promote regional identity in the Drosophila head. | Q52100462 | ||
| EGF receptor and Notch signaling act upstream of Eyeless/Pax6 to control eye specification. | Q52138123 | ||
| Spatiotemporal Evolution of the Primary Glioblastoma Genome. | Q52149231 | ||
| Epidemiologic and molecular prognostic review of glioblastoma | Q28395302 | ||
| Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance | Q28550264 | ||
| Molecular cloning of a protein serine/threonine phosphatase containing a putative regulatory tetratricopeptide repeat domain | Q28572515 | ||
| Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis | Q28584911 | ||
| Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma | Q29615604 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. | Q30252408 | ||
| Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration | Q30409822 | ||
| Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma | Q30428996 | ||
| Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas | Q30531068 | ||
| Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. | Q31856389 | ||
| FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells | Q31952928 | ||
| Discovery of a novel shp2 protein tyrosine phosphatase inhibitor | Q33244294 | ||
| Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages | Q33478364 | ||
| Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth | Q33770873 | ||
| Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development | Q33776641 | ||
| Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas | Q33881165 | ||
| Neuroprotectin D1 induces dephosphorylation of Bcl-xL in a PP2A-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival | Q33897738 | ||
| Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells. | Q33912275 | ||
| Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism | Q33965102 | ||
| Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers | Q34104555 | ||
| Identification of prognostic biomarkers for glioblastomas using protein expression profiling | Q34104795 | ||
| Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia | Q34130984 | ||
| Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies | Q34132781 | ||
| Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). | Q34155125 | ||
| Protein tyrosine phosphatases as potential therapeutic targets | Q34295063 | ||
| Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty | Q34307028 | ||
| Mutational analysis of the tyrosine phosphatome in colorectal cancers | Q34322220 | ||
| Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma | Q34391844 | ||
| Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. | Q34393314 | ||
| Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility | Q34483732 | ||
| Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis | Q34491156 | ||
| Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis | Q34503441 | ||
| Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis | Q34607187 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein phosphatase | Q2746739 |
| signaling | Q14865172 | ||
| P304 | page(s) | 241 | |
| P577 | publication date | 2019-02-19 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Protein Phosphatases-A Touchy Enemy in the Battle Against Glioblastomas: A Review | |
| P478 | volume | 11 |
| Q92344401 | Glioblastoma: State of the Art and Future Perspectives |
| Q102203509 | Small molecule inhibitors of Shp2 phosphatase as potential chemotherapeutic agents for glioblastoma: A mini-review |
Search more.